Agios Receives FDA Orphan Drug Designation for Tebapivat in Myelodysplastic Syndromes
Details : AG-946 (tebapivat) is an investigational pyruvate kinase (PK) activator, which is under clinical development fot the potential treatment for anemia in adults with lower-risk myelodysplastic syndromes.
Brand Name : AG-946
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 11, 2024
Details : AG-946 is an investigational pyruvate kinase (PK) activator, which is under clinical development fot the potential treatment for anemia in adults with lower-risk myelodysplastic syndromes (LR-MDS).
Brand Name : AG-946
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 20, 2023
Lead Product(s) : Tebapivat
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AG-946, is a novel small molecule that activates the enzyme pyruvate kinase which contributes to the production of energy in the RBC. By helping to increase energy, RBC functionality and survival may be improved.
Brand Name : AG-946
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 03, 2022
Lead Product(s) : Tebapivat
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
